1. Generics Bulletin
  2. >>Business
  3. >>Deals

Zentiva Sees Success With Apontis Buyout

Captures Just Over 85% Of Voting Rights After Voluntary Public Purchase Offer

 
• By Dave Wallace

Zentiva is moving ahead with its takeover of Apontis Pharma after its voluntary public purchase offer resulted in it securing almost 84% of share capital and a more than 85% share of voting rights.

Zentiva will move ahead with its takeover of Apontis (Shutterstock)

Zentiva has revealed the result of its previously-announced bid to take control of “single pill company” Apontis Pharma – and the outcome is positive for the buyer, with Zentiva’s voluntary public purchase offer ultimately securing 83.57% of Apontis share capital and 85.27% of voting rights.

Announced in mid-October, Zentiva’s offer valued Germany’s Apontis at €85m ($92.2m), with Zentiva having already secured a stake of 37

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

UK-India FTA Could Offer ‘Significant Benefits’ For Generics And Biosimilars

 
• By Dave Wallace

A free trade agreement struck between the UK and India could over “significant benefits for the generic and biosimilar sectors,” Medicines UK believes. The off-patent industry association has also suggested further avenues for collaboration between the two governments on regulatory pathways and supply security.

Tetris Deal Falls Into Place For UK’s Aspire

 
• By Dave Wallace

Niche generics company Aspire Pharma has struck a deal to acquire a portfolio of products from fellow UK firm Tetris Pharma as it is wound up, paying Tetris parent Arecor £0.5m for UK distribution rights and inventory.

Apotex Extends Formosa Ophthalmic Alliance Into Mexico

 
• By Dave Wallace

Apotex has expanded an alliance formed with Formosa in August for its novel clobetasol propionate ophthalmic treatment, adding Mexican rights to its existing deal for the Canadian market.

Adalvo And Gedeon Richter Join Forces On Semaglutide

 
• By Dave Wallace

Adalvo and Gedeon Richter have announced a global co-development deal for semaglutide for obesity. Adalvo CEO Anil Okay spoke to Generics Bulletin about the alliance as well as the broader competitive landscape for GLP-1s.

More from Strategy